cyclic-gmp and 8-bromoguanosine

1. We tested the hypothesis that the cGMP-dependent protein kinase has major negative functional effects in cardiac myocytes and that the importance of this pathway is reduced in thyroxine (T4; 0.5 mg/kg per day for 16 days) hypertrophic myocytes. 2. Using isolated ventricular myocytes from control (n = 7) and T4-treated (n = 9) rabbit hypertrophic hearts, myocyte shortening was studied with a video edge detector. Oxygen consumption was measured using O2 electrodes. Protein phosphorylation was measured autoradiographically. 3. Data were collected following treatment with: (i) 8-(4-chlorophenylthio)guanosine-3',5'-monophosphate (PCPT; 10-7 or 10-5 mol/L); (ii) 8-bromo-cAMP (10-5 mol/L) followed by PCPT; (iii) beta-phenyl-1,N2-etheno-8-bromoguanosine-3',5'-monophosphorothioate, SP-isomer (SP; 10-7 or 10-5 mol/L); or (iv) 8-bromo-cAMP (10-5 mol/L) followed by SP. 4. There were no significant differences between groups in baseline percentage shortening (Pcs; 4.9 +/- 0.2 vs 5.6 +/- 0.4% for control and T4 groups, respectively) and maximal rate of shortening (Rs; 64.8 +/- 5.9 vs 79.9 +/- 7.1 micro m/ s for control and T4 groups, respectively). Both SP and PCPT decreased Pcs (-43 vs-21% for control and T4 groups, respectively) and Rs (-36 vs-22% for control and T4 groups, respectively), but the effect was significantly reduced in T4 myocytes. 8-Bromo-cAMP similarly increased Pcs (28 vs 23% for control and T4 groups, respectively) and Rs (20 vs 19% for control and T4 groups, respectively). After 8-bromo-cAMP, SP and PCPT decreased Pcs (-34%) and Rs (-29%) less in the control group. However, the effects of these drugs were not altered in T4 myocytes (Pcs -24%; Rs -22%). Both PCPT and cAMP phosphorylated the same five protein bands. In T4 myocytes, these five bands were enhanced less. 5. We conclude that, in control ventricular myocytes, the cGMP-dependent protein kinase exerted major negative functional effects but, in T4-induced hypertrophic myocytes, the importance of this pathway was reduced and the interaction between cAMP and the cGMP protein kinase was diminished.

Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Body Weight; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Drug Administration Schedule; Drug Synergism; gamma-Aminobutyric Acid; Guanosine; Heart Ventricles; Hypertrophy; Injections, Intramuscular; Myocardial Contraction; Myocytes, Cardiac; Organ Size; Oxygen Consumption; Phosphoproteins; Phosphorylation; Rabbits; Stimulation, Chemical; Thyroxine; Time Factors

The effects of a monoclonal antibody (B8E5) directed against the second extracellular loop of the muscarinic M(2) receptor were studied on the L-type Ca(2+) currents (I(Ca,L)) of guinea pig ventricular myocytes using the whole cell patch-clamp technique. Similar to carbachol, B8E5 reduced the isoproterenol (ISO)-stimulated I(Ca,L) but did not significantly affect basal I(Ca,L). Atropine blocked the inhibitory effect of B8E5. The electrophysiological parameters of ISO-stimulated I(Ca,L) were not modified in presence of B8E5. Inhibition of I(Ca,L) by B8E5 was still observed when intracellular cAMP was either enhanced by forskolin or maintained constant by using a hydrolysis-resistant cAMP analog (8-bromoadenosine 3',5'-cyclic monophosphate) or by applying the phosphodiesterase inhibitor IBMX. The effect of B8E5 was mimicked by 8-bromoguanosine 3',5'-cyclic monophosphate, a potent stimulator of cGMP-dependent protein kinase, and prevented by a selective inhibitor of nitric oxide-sensitive guanylyl cyclase [1H-(1,2,4)oxadiazolo[4,3-a]quinoxaline-1-one]. These results indicate that the antibody B8E5 inhibits the beta-adrenergic-stimulated I(Ca,L) through activation of the M(2) muscarinic receptor and further suggest that the antibody acts not via the classical pathway of decreasing intracellular cAMP, but rather by increasing cGMP.

Topics: 1-Methyl-3-isobutylxanthine; 8-Bromo Cyclic Adenosine Monophosphate; Adrenergic beta-Agonists; Animals; Antibodies, Monoclonal; Autoantibodies; Calcium Channels, L-Type; Colforsin; Cyclic GMP; Enzyme Inhibitors; Guanosine; Guinea Pigs; Heart Ventricles; In Vitro Techniques; Isoproterenol; Membrane Potentials; Muscle Fibers, Skeletal; Myocardium; Oxadiazoles; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Quinoxalines; Receptor, Muscarinic M2; Receptors, Muscarinic

Lymphokine-like activity and selective stimulation of B cell growth is exerted by a group of synthetic ribonucleosides derivatized at C8 and exemplified by 8-bromoguanosine (8BrGuo), 8-mercaptoguanosine, and 7-methyl 8-oxoguanosine. However, relatively little is known about their molecular mechanism of action. Like naturally occurring nucleosides, 8BrGuo is taken up into lymphocytes by a process of facilitated diffusion. Naturally occurring nucleosides are then reclaimed by a well characterized salvage pathway, involving sequential phosphorolysis and phosphoribosylation. The studies reported in this communication demonstrate that, in contrast to naturally occurring nucleosides, 8BrGuo is not a substrate for salvage by purine nucleoside phosphorylase. The base that would be produced by putative phosphorolysis, 8-bromoguanine, is biologically inactive and is not a substrate for hypoxanthine-guanine phosphoribosyl-transferase. Accordingly, inhibitors of purine nucleoside phosphorylase-mediated salvage fail to inhibit nucleoside-induced immunostimulation selectively. Examination of the metabolism of 8BrGuo provides no direct evidence that 8BrGuo is phosphorylated by B lymphocytes. Direct enzymatic phosphorylation does not seem to be essential to the mechanism of action of the nucleoside insofar as competitive inhibition of deoxycytidine kinase (an enzyme that directly phosphorylates purines as well as pyrimidines) or of deoxyguanosine kinase fails to inhibit 8BrGuo stimulation selectively. Moreover, studies with synthetic nucleosides in which 3' and/or 5' hydroxyl groups were irreversibly blocked, precluding their phosphorylation, demonstrated that immunobiologic activity can occur in the absence of 3' and/or 5' phosphorylation. Finally, experiments with radiolabeled nucleosides provide no evidence to support the hypothesis that they are incorporated into cellular nucleic acid. These data, together with previous studies, suggest that it is the unmetabolized nucleoside that is active and, as such, is most likely to act in a regulatory capacity.

Topics: Adjuvants, Immunologic; Animals; B-Lymphocytes; Cells, Cultured; Cyclic GMP; DNA; Guanosine; Humans; Lymphocyte Activation; Male; Mice; Mice, Inbred CBA; Mitogens; Phosphorylation; Protein Synthesis Inhibitors; RNA

Cholinergic-mediated amylase release in mouse parotid acini was augmented by forskolin; the potency but not the maximal response to carbachol was altered. Amylase released by carbachol plus forskolin was dependent on extracellular calcium and was mimicked by the calcium ionophore, A23187 plus forskolin. Forskolin was also shown to enhance carbachol-stimulated 45Ca2+ uptake into isolated acini. Hydroxylamine, nitroprusside, and 8-bromo-c-GMP each in combination with forskolin mimicked the effects of carbachol plus forskolin on amylase release. In the presence of carbachol (10(-8)M) forskolin did not augment c-AMP levels. However, in the presence of carbachol (5 X 10(-7) M) or hydroxylamine (50 microM) forskolin did significantly augment c-AMP accumulation. These results suggest that calcium and c-GMP may mediate the augmentation of cholinergic-mediated amylase release by effects on c-AMP metabolism.

Topics: Amylases; Animals; Calcimycin; Calcium; Carbachol; Colforsin; Cyclic GMP; Drug Synergism; Guanosine; Hydroxylamine; Hydroxylamines; Isoproterenol; Mice; Nitroprusside; Parasympathomimetics; Parotid Gland

Guanine ribonucleosides, substituted at the C8 position with either a bromine or thiol group, are potent adjuvants when added to culture with antigen. Responses from both naive and antigen-experienced B cells are augmented by the presence of the nucleoside derivatives. Like the induction of B cell proliferation and polyclonal immunoglobulin secretion, enhancement of antibody responses is not attributable to structural analogy between 8BrGuo and the cyclic nucleotide 8Br-cGMP, because the latter compound is unable to augment the antibody response. The capacity of 8MGuo to augment both T-independent and T helper factor-supported antibody responses suggests that the nucleoside acts by directly interacting with B cells and/or antigen-presenting cells. 8MGuo retains its full adjuvant activity even when added 3 days after culture initiation, a time that is too late for freshly added T cells to support a response. Finally, supplementation of cultures of spleen cells from immunodeficient (CBA/N x CBA/CaJ)F1 male mice with the nucleoside effectively restored to normal their capacity to generate an antibody response.

Topics: Adjuvants, Immunologic; Animals; Antigens, T-Independent; Cyclic GMP; Guanosine; Immunoglobulin G; Immunoglobulin M; Immunologic Deficiency Syndromes; Isoantibodies; Male; Mice; Mice, Inbred CBA; T-Lymphocytes; Thionucleosides